-
公开(公告)号：US20170087127A1
公开(公告)日：2017-03-30
申请号：US15343859
申请日：2016-11-04
IPC分类号： A61K31/40
CPC分类号： A61K31/40 , Y10S514/893
摘要： The present invention provides a compound of Formula (I) or pharmaceutical acceptable thereof, wherein ‘R’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (I) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (NAFLD) including fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), and cirrhosis (advanced scarring of the liver).
-
公开(公告)号：US20180185330A1
公开(公告)日：2018-07-05
申请号：US15801738
申请日：2017-11-02
IPC分类号： A61K31/40
CPC分类号： A61K31/40 , Y10S514/893
摘要： The present invention provides a compound of Formula (I) or pharmaceutical acceptable thereof, wherein ‘R’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (I) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (NAFLD) including fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), and cirrhosis (advanced scarring of the liver).
-
3.发明申请2-PHENYL-5-HETEROCYCLYL-TETRAHYDRO-2H-PYRAN-3-AMINE COMPOUNDS FOR USE IN THE TREATMENT OF DIABETES AND ITS ASSOCIATED DISORDERS 审中-公开用于治疗糖尿病及其相关疾病的2-苯基-5-间苯二甲酸四氢-2H- -2H-吡喃-3-胺化合物公开(公告)号：US20150246025A1
公开(公告)日：2015-09-03
申请号：US14436504
申请日：2013-10-17
IPC分类号： A61K31/437 , A61K31/407 , A61K45/06 , C07D487/10 , A61K31/403 , C07D471/04 , C07D471/10 , A61K31/435 , C07D405/04 , C07D487/04 , C07D491/048
CPC分类号： A61K31/437 , A61K31/403 , A61K31/407 , A61K31/435 , A61K45/06 , C07D405/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/04 , C07D491/048 , C07D495/04
摘要： The present invention relates to novel compounds of the general formula (I) their tautomeric forms, their enantiomers, their diastereoisomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment or prevention of diabetes mellitus (DM), obesity and other metabolic disorders. The invention also relates to process for the manufacture of said compounds, and pharmaceutical compositions containing them and their use.
摘要翻译： 本发明涉及用于治疗或预防糖尿病（DM）的通式（I）的新型化合物，其互变异构形式，其对映异构体，其非对映异构体，其药学上可接受的盐或其前体药物， 肥胖等代谢紊乱。 本发明还涉及制备所述化合物的方法和含有它们的药物组合物及其用途。
-
公开(公告)号：US09814697B2
公开(公告)日：2017-11-14
申请号：US15343859
申请日：2016-11-04
IPC分类号： A61K31/40
CPC分类号： A61K31/40 , Y10S514/893
摘要： The present invention provides a compound of Formula (I) or pharmaceutical acceptable thereof, wherein ‘R’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (I) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (NAFLD) including fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), and cirrhosis (advanced scarring of the liver).
-
公开(公告)号：US09556148B2
公开(公告)日：2017-01-31
申请号：US14910028
申请日：2014-08-06
发明人： Ranjit Desai , Jigar Desai , Pankaj Patel
IPC分类号： C07D401/14 , C07D417/14 , C07D413/14 , C07D403/14 , C07D409/10 , C07D409/14 , C07D498/08 , C07D513/08 , C07D401/12 , C07D403/12 , C07D405/14 , C07D407/12 , C07D407/14 , C07D409/12 , C07D471/08 , C07D491/056 , C07D491/08 , C07D491/107 , C07D495/08
CPC分类号： C07D401/14 , C07D401/12 , C07D403/12 , C07D403/14 , C07D405/14 , C07D407/12 , C07D407/14 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D491/056 , C07D491/08 , C07D491/107 , C07D495/08 , C07D498/08 , C07D513/08
摘要： The present invention relates to compounds of general formula (1) that are inhibitors of Janus Kinase (JAK), a family of tyrosine kinases that are involved in inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. In particular, the compound of the invention inhibits JAK1 and/or JAK2 and/or JAK3 sub families. The present invention also provides methods for the production of the compounds of the invention, pharmaceutical compositions comprising the compounds of the invention, their tautomeric forms, and their pharmaceutically acceptable salts
摘要翻译： 本发明涉及作为炎性病症，自身免疫性疾病，增殖性疾病，变态反应，移植排斥，涉及软骨损害的疾病的酪氨酸激酶家族的Janus Kinase（JAK）抑制剂的通式（1）的化合物 周转，先天性软骨畸形和/或与IL6或干扰素分泌过多相关的疾病。 特别地，本发明的化合物抑制JAK1和/或JAK2和/或JAK3亚族。 本发明还提供了制备本发明化合物的方法，包含本发明化合物，其互变异构形式及其药学上可接受的盐的药物组合物
-
-
-
-
搜索结果
5 条记录 (耗时 0.013 秒)
